Form 4: Catalyst Pharma Director Converts RSUs to Common Stock

Catalyst Pharmaceuticals Director Molly Harper converted 1,334 restricted stock units into common stock on December 29, 2025, as part of a pre-planned vesting schedule.

Summary

• Molly Harper, a Director at Catalyst Pharmaceuticals, Inc. (CPRX), reported a change in beneficial ownership.
• On December 29, 2025, 1,334 restricted stock units (RSUs) were converted into 1,334 shares of the Registrant's common stock.
• The RSUs vested in equal tranches: 1/3rd on December 27, 2023, 1/3rd on December 27, 2024, and the final 1/3rd on December 27, 2025.
• Shares of common stock are required to be delivered within sixty days of vesting, with the final tranche delivered on December 29, 2025.
• Following this transaction, Molly Harper directly beneficially owns 3,694 shares of common stock.
• Molly Harper directly beneficially owns 127,163 restricted stock units after this transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine, pre-scheduled insider transaction (vesting and conversion of RSUs) which increases the director's direct ownership, generally seen as a positive alignment of interests. There are no negative implications from this specific filing.

Positives

• The conversion of restricted stock units into common stock increases the director's direct equity ownership in Catalyst Pharmaceuticals, aligning their interests more closely with shareholders.
• The transaction is a result of a pre-planned vesting schedule, indicating a routine compensation event rather than a discretionary sale.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

Insider transactions, particularly those related to the vesting and conversion of equity awards, are common in publicly traded companies. Such events typically reflect pre-established compensation plans for executives and directors, rather than discretionary trading based on new material information.

Stakeholder Impact

• Shareholders: The transaction increases the direct equity ownership of a director, which can be viewed positively as it aligns management's interests with those of shareholders.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Molly Harper, Director, Restricted Stock Units, RSU conversion, Common Stock, Insider Transaction, SEC Form 4, Beneficial Ownership, Vesting